Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8TBK2
UPID:
SETD6_HUMAN
Alternative names:
SET domain-containing protein 6
Alternative UPACC:
Q8TBK2; A8K380; B5ME38; Q9H787
Background:
N-lysine methyltransferase SETD6, also known as SET domain-containing protein 6, plays a crucial role in cellular processes. It is involved in the methylation of 'Lys-310' of the RELA subunit of the NF-kappa-B complex, leading to the down-regulation of NF-kappa-B transcription factor activity. Additionally, SETD6 monomethylates 'Lys-8' of H2AZ, contributing to the regulation of gene expression. Its activity is essential for the maintenance of embryonic stem cell self-renewal.
Therapeutic significance:
Understanding the role of N-lysine methyltransferase SETD6 could open doors to potential therapeutic strategies. Its involvement in key cellular processes and gene expression regulation highlights its potential as a target in developing treatments for conditions where these pathways are dysregulated.